Ionis Pharmaceuticals, Inc. Amortization of Debt Discount (Premium)
Ionis Pharmaceuticals, Inc. (IONS) reported Amortization of Debt Discount (Premium) of $36.16 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2021-02-24
- Ionis Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2020-12-31 was $9.24M, a 12.71% decline year-over-year.
- Ionis Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2020-09-30 was $9.11M, a 0.21% increase year-over-year.
- Ionis Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2020-06-30 was $8.97M, a 0.43% increase year-over-year.
- Ionis Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2020-03-31 was $8.83M, a 1.24% increase year-over-year.
- Ionis Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2020 was $36.16M, a 3.16% decline from fiscal 2019.
- Ionis Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2019 was $37.34M, a 11.91% increase from fiscal 2018.
- Ionis Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2018 was $33.36M, a 7.90% increase from fiscal 2017.
- Ionis Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2017 was $30.92M, a 29.43% increase from fiscal 2016.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $9.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $18.35M derived: sum of 2 quarters · filed 2021-02-24 | $27.32M derived: sum of 3 quarters · filed 2021-02-24 | $36.16M 10-K · filed 2021-02-24 | |
| 2020-09-30 | $9.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $18.08M derived: sum of 2 quarters · filed 2020-11-04 | $26.91M 10-Q · filed 2020-11-04 | $37.50M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2020-06-30 | $8.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $17.81M 10-Q · filed 2020-08-05 | $28.40M derived: sum of 3 quarters · filed 2021-02-24 | $37.48M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2020-03-31 | $8.83M 10-Q · filed 2020-05-06 | $19.43M derived: sum of 2 quarters · filed 2021-02-24 | $28.51M derived: sum of 3 quarters · filed 2021-02-24 | $37.45M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-12-31 | $10.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $19.68M derived: sum of 2 quarters · filed 2021-02-24 | $28.61M derived: sum of 3 quarters · filed 2021-02-24 | $37.34M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $9.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $18.02M derived: sum of 2 quarters · filed 2020-11-04 | $26.75M 10-Q · filed 2020-11-04 | $35.33M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $8.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $17.66M 10-Q · filed 2020-08-05 | $26.24M derived: sum of 3 quarters · filed 2021-02-24 | $34.66M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $8.73M 10-Q · filed 2020-05-06 | $17.31M derived: sum of 2 quarters · filed 2021-02-24 | $25.73M derived: sum of 3 quarters · filed 2021-02-24 | $34.01M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $17.00M derived: sum of 2 quarters · filed 2021-02-24 | $25.28M derived: sum of 3 quarters · filed 2021-02-24 | $33.36M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $8.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $16.70M derived: sum of 2 quarters · filed 2019-11-06 | $24.78M 10-Q · filed 2019-11-06 | $32.74M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | $8.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $16.36M 10-Q · filed 2019-08-08 | $24.32M derived: sum of 3 quarters · filed 2020-03-02 | $32.12M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $8.08M 10-Q · filed 2019-05-09 | $16.04M derived: sum of 2 quarters · filed 2020-03-02 | $23.84M derived: sum of 3 quarters · filed 2020-03-02 | $31.50M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | $7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $15.76M derived: sum of 2 quarters · filed 2020-03-02 | $23.41M derived: sum of 3 quarters · filed 2020-03-02 | $30.92M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $7.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $15.46M derived: sum of 2 quarters · filed 2018-11-06 | $22.96M 10-Q · filed 2018-11-06 | $29.11M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | $7.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $15.16M 10-Q · filed 2018-08-07 | $21.32M derived: sum of 3 quarters · filed 2019-03-01 | $27.34M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | $7.51M 10-Q · filed 2018-05-07 | $13.66M derived: sum of 2 quarters · filed 2019-03-01 | $19.69M derived: sum of 3 quarters · filed 2019-03-01 | $25.60M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2016-12-31 | $6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $12.18M derived: sum of 2 quarters · filed 2019-03-01 | $18.09M derived: sum of 3 quarters · filed 2019-03-01 | $23.89M 10-K · filed 2019-03-01 | |
| 2016-09-30 | $6.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $11.94M derived: sum of 2 quarters · filed 2017-11-07 | $17.74M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $5.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $11.71M 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | $5.79M 10-Q · filed 2017-05-09 | ||||
| 2015-12-31 | $22.07M 10-K · filed 2018-02-28 | ||||
| 2013-12-31 | $6.30M 10-K · filed 2014-03-03 | ||||
| 2012-12-31 | $8.40M 10-K · filed 2014-03-03 | ||||
| 2011-12-31 | $8.60M 10-K · filed 2014-03-03 | $8.55M 10-K · filed 2012-02-29 | |||
| 2010-12-31 | $7.80M 10-K · filed 2013-02-28 | $7.79M 10-K · filed 2011-03-01 | |||
| 2009-12-31 | $7.11M 10-K · filed 2012-02-29 | ||||
| 2008-12-31 | $6.48M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |